Precigen, Inc. Common Stock
PGENPrecigen, Inc. is a biotechnology company focused on the development of gene and cell therapies, immunotherapies, and advanced genetic medicines. It aims to address unmet medical needs across various indications, including cancer, infectious diseases, and autoimmune disorders, through innovative platform technologies and proprietary scientific approaches.
Company News
Patient Capital Management increased its stake in Precigen by 10.2 million shares in Q3 2025, valuing the transaction at approximately $28.78 million. The investment represents 3.48% of the fund's assets under management, following Precigen's significant stock price surge after FDA approval of Papzimeos.
Two healthcare stocks, Precigen and Mineralys Therapeutics, have seen significant stock price increases recently due to FDA approval and promising clinical trial results in rare disease treatment and hypertension medication development.
Precigen has submitted a biologics license application to the FDA for PRGN-2012, a potential first treatment for recurrent respiratory papillomatosis. The submission is a significant step forward, as PRGN-2012 has received Breakthrough Therapy and Orphan Drug Designations from the FDA.
Precigen (NASDAQ:PGEN) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewha...
